C-reactive protein and cardiovascular disease: new insights from an old molecule

被引:177
作者
Hirschfield, GM [1 ]
Pepys, MB [1 ]
机构
[1] UCL Royal Free & Univ Coll, Sch Med, Ctr Amyloidosis & Acute Phase Prot, Dept Med, London NW3 2PF, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
D O I
10.1093/qjmed/hcg134
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The classical acute-phase protein, C-reactive protein (CRP), is an exquisitely sensitive systemic marker of disease with broad clinical utility for monitoring and differential diagnosis. Inflammation, the key regulator of CRP synthesis, plays a pivotal role in atherothrombotic cardiovascular disease. There is a powerful predictive association between raised serum CRP values and the outcome of acute coronary syndromes, and, remarkably, between even modestly increased CRP production and future atherothrombotic events in otherwise healthy individuals. Baseline CRP values also reflect metabolic states associated with atherothrombotic events. The presence of CRP within most atherosclerotic plaques and all acute myocardial infarction lesions, coupled with binding of CRP to lipoproteins and its capacity for pro-inflammatory complement activation, suggests that CRP may contribute to the pathogenesis and complications of cardiovascular disease. We review the biological properties of CRP, the association between CRP and cardiovascular disease, and the possibility that CRP may be a novel therapeutic target.
引用
收藏
页码:793 / 807
页数:15
相关论文
共 178 条
  • [1] A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide
    Agrawal, A
    Simpson, MJ
    Black, S
    Carey, MP
    Samols, D
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 169 (06) : 3217 - 3222
  • [2] Transactivation of c-reactive protein by IL-6 requires synergistic interaction of CCAAT/enhancer finding protein β (C/EBPβ) and Rel p50
    Agrawal, A
    Cha-Molstad, H
    Samols, D
    Kushner, I
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (04) : 2378 - 2384
  • [3] Topology and structure of the C1q-binding site on C-reactive protein
    Agrawal, A
    Shrive, AK
    Greenhough, TJ
    Volanakis, JE
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (06) : 3998 - 4004
  • [4] Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
    Albert, MA
    Danielson, E
    Rifai, N
    Ridker, PM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01): : 64 - 70
  • [5] Alcohol consumption and plasma concentration of C-reactive protein
    Albert, MA
    Glynn, RJ
    Ridker, PM
    [J]. CIRCULATION, 2003, 107 (03) : 443 - 447
  • [6] Anzai T, 1997, CIRCULATION, V96, P778
  • [7] End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?
    Arici, M
    Walls, J
    [J]. KIDNEY INTERNATIONAL, 2001, 59 (02) : 407 - 414
  • [8] C-reactive protein levels are influenced by common Il-1 gene variations
    Berger, P
    McConnell, JP
    Nunn, M
    Kornman, KS
    Sorrell, J
    Stephenson, K
    Duff, GW
    [J]. CYTOKINE, 2002, 17 (04) : 171 - 174
  • [9] ELEVATION OF C-REACTIVE PROTEIN IN ACTIVE CORONARY-ARTERY DISEASE
    BERK, BC
    WEINTRAUB, WS
    ALEXANDER, RW
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (03) : 168 - 172
  • [10] Complement and atherogenesis - Binding of CRP to degraded, nonoxidized LDL enhances complement activation
    Bhakdi, S
    Torzewski, M
    Klouche, M
    Hemmes, M
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (10) : 2348 - 2354